Cost Analysis of Prostate Cancer Screening
Author Information
Author(s): Ekwueme Donatus U, Stroud Leonardo A, Chen Yanjing
Primary Institution: Centers for Disease Control and Prevention
Hypothesis
What are the resource costs associated with prostate cancer screening, diagnostic testing, and clinical staging in the United States compared to other industrialized countries?
Conclusion
Understanding the resource costs of prostate cancer screening is essential for health policy makers to make informed decisions about resource allocation.
Supporting Evidence
- The pooled baseline resource cost for screening with PSA in the U.S. was $37.23.
- The average resource cost of screening with PSA decreased by $20.64 from 1993 to 2002.
- Resource costs for diagnostic methods were found to be higher in the U.S. compared to other countries.
Takeaway
This study looked at how much it costs to test for prostate cancer in the U.S. and other countries, helping people decide if it's worth the money.
Methodology
The study reviewed 262 articles on prostate cancer costs published from 1980 to 2003, selecting 28 that met specific criteria and using statistical methods to analyze the data.
Potential Biases
Potential bias may arise from the variability in how resource costs were reported and measured across different studies.
Limitations
The study's findings are based on pooled data from various studies with different populations and settings, which may affect the accuracy of the resource cost estimates.
Participant Demographics
Participants in the studies ranged from 40 to 93 years old, with varying numbers of men screened and biopsies performed.
Statistical Information
Confidence Interval
95% CI for costs reported in the study.
Want to read the original?
Access the complete publication on the publisher's website